Trial · NCT02277093
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Pacritinib | 1.91 | Inter-Quartile Range 1.81 to 8.75 | months | |
| Toxicity Profile and Tolerability as Measured by Reportable Adverse Events | Pacritinib | Diarrhea | 1 | adverse event | |
| Toxicity Profile and Tolerability as Measured by Reportable Adverse Events | Pacritinib | Edema limbs | 1 | adverse event | |
| Toxicity Profile and Tolerability as Measured by Reportable Adverse Events | Pacritinib | Edema face | 1 | adverse event | |
| Toxicity Profile and Tolerability as Measured by Reportable Adverse Events | Pacritinib | Fatigue | 1 | adverse event | |
| Toxicity Profile and Tolerability as Measured by Reportable Adverse Events | Pacritinib | Localized edema | 1 | adverse event | |
| Toxicity Profile and Tolerability as Measured by Reportable Adverse Events | Pacritinib | Blood bilirubin increased | 1 | adverse event | |
| Toxicity Profile and Tolerability as Measured by Reportable Adverse Events | Pacritinib | Dyspnea | 1 | adverse event | |
| Toxicity Profile and Tolerability as Measured by Reportable Adverse Events | Pacritinib | Rash maculopapular | 1 | adverse event | |
| Overall Response Rate (ORR) | Pacritinib | Complete response | 0 | Participants | |
| Overall Response Rate (ORR) | Pacritinib | Partial response | 0 | Participants | |
| Overall Response Rate (ORR) | Pacritinib | Stable disease | 1 | Participants | |
| Overall Response Rate (ORR) | Pacritinib | Progressive disease | 6 | Participants | |
| Overall Response Rate (ORR) | Pacritinib | Not evaluable | 4 | Participants | |
| Time to Progression (TTP) | Pacritinib | 1.73 | Standard Deviation 0.26 | months | |
| Overall Survival (OS) | Pacritinib | 6.61 | 95% Confidence Interval 2.79 to 9.34 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02277093/results